Stifel Maintains Hold on Travere Therapeutics, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Alex Thompson has maintained a Hold rating on Travere Therapeutics (NASDAQ:TVTX) and increased the price target from $8 to $10.

December 18, 2023 | 3:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Alex Thompson maintains a Hold rating on Travere Therapeutics and raises the price target from $8 to $10.
The increase in price target by Stifel suggests a positive outlook on the stock's value, which could lead to increased investor confidence and a potential short-term rise in the stock price. However, the Hold rating indicates that the analyst does not see significant momentum or changes in the company's fundamentals to warrant a Buy rating at this time.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100